SecBot SecBot
S-4 ·Filed Nov 3, 2026

ADCT

ADC Therapeutics SA
NEUTRAL
Impact 3/10
Horizonmonths Processed13d 6h ago SEC0000950103-26-016858
Notable filing: S-4
Actionable Insight • Neutral

Monitor shareholder vote and satisfaction of conditions (Swiss tax rulings, SEC effectiveness, NYSE listing). The transaction is routine but completion risk exists if conditions are not met by mid-2027.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5
Entry
$1.72
T+0 close · Nov 3, 2026 · via day close
Latest settled
−6.98%
T+5 · $1.60 · next T+20 in 16d
Vs SPY
−6.06%
α at T+5
Latest observation
−20.05%
T+7 · FF3 residual α
  1. T+0 · Nov 4 $1.72entry
  2. T+1 · 12d ago −4.65%α −0.24% · $1.64
  3. T+5 · 6d ago −6.98%α −6.06% · $1.60
  4. T+8 · todayOpen
  5. T+20 · in 16d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ADC Therapeutics SA filed a preliminary S-4 registration statement to reincorporate from Switzerland to Delaware via a redomiciliation transaction. The transaction requires shareholder approval and is expected to close by June 30, 2027, with no change in business, capitalization, or shareholder economic interest. The filing is a routine corporate restructuring with no material financial impact.

Key Facts

  • Board unanimously approved redomiciliation from Switzerland to Delaware under name ADC Therapeutics, Inc.
  • Each issued Swiss common share (CHF 0.08 par value) will convert 1:1 into Delaware common stock ($0.10 par value).
  • No dilution; outstanding share count unchanged post-transaction.
  • Transaction conditioned on shareholder approval, SEC effectiveness, NYSE listing, Swiss tax rulings, and creditor protections.
  • If not consummated by June 30, 2027, the approval lapses.
  • No material accounting effect; no pro forma financials included.
  • Market cap ~$190M; stock price $1.54 on Nov 2, 2026.
  • No change in business, assets, liabilities, board, or management expected.

Financial Impact

No material financial impact; transaction is a change of domicile only.

Risk Factors

  • Transaction may not be consummated if conditions (tax rulings, creditor protections, regulatory approvals) are not satisfied by June 30, 2027.
  • Potential Swiss withholding tax exposure if market cap exceeds nominal capital plus reserves, though currently considered unlikely.
  • U.S. tax consequences for holders under Section 367(b) and PFIC rules; complexity may deter some investors.
  • Shareholder lawsuits could delay or prevent completion.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
S-4 Filing (Primary)0000950103-26-016858
Document: dp256030_exfilingfees.htm0000950103-26-016858
Document: dp256030_ex2301.htm0000950103-26-016858
Document: 0000950103-26-016858-index-headers.html0000950103-26-016858
Document: 0000950103-26-016858-index.html0000950103-26-016858
Document: 0000950103-26-016858.txt0000950103-26-016858

Track record

14 reports on ADCT

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $1.41 Now $1.25 −11.35% settles Dec 15
  2. Nov 9, 20267d ago S-3 Neutral 3/10 Entry $1.51 Now $1.25 −17.22% settles Dec 9
  3. Nov 9, 20267d ago 8-K Neutral 4/10 Entry $1.67 Now $1.25 −25.15% settles Dec 8
  4. Nov 4, 202612d ago 8-K Mixed 6/10 Entry $1.64 Now $1.25 −23.78% settles Dec 4
  5. Nov 3, 202613d ago S-4 Neutral 3/10 Viewing Entry $1.72 Now $1.25 −27.33% settles Dec 3
  6. Oct 29, 202618d ago SC 13G Neutral 4/10 Entry $1.53 Now $1.25 −18.30% settles Nov 30
  7. Oct 13, 20264w ago 8-K Bullish 7/10 Entry $1.70 to $1.51 Now $1.25 −26.47% ▼ −11.18% −7.57% vs SPY
  8. Aug 6, 202614w ago Press Release Neutral 1/10 Entry $1.13 to $1.32 Now $1.25 +10.62% ▲ +16.81% +16.21% vs SPY
  9. Jul 2, 202619w ago 8-K Neutral 2/10 Entry $1.19 to $1.11 Now $1.25 +5.04% ▼ −6.72% −6.31% vs SPY
  10. Jun 3, 202623w ago 8-K Mixed 6/10 Entry $1.32 to $1.19 Now $1.25 −5.30% ▼ −9.85% −8.48% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens Wed (10h 21m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026